Markus from Chile

Registered at the short selling broker Capital, 5 minutes ago.

» Try Capital you too
71.2% of retail investor accounts lose money when trading CFDs with Capital.
Don't show again

Banco Santander SA (SAN) shares information

Banco Santander S.A. – ADR

24h Change

1.28 %


Live rate: Market closed

Stock data per Monday 10 May, 2021

0.05 (+ 1.28%)
US Market is closed

Live Stock price in graph for Banco Santander S.A. – ADR (SAN)

  • Latest Volume

    6,398,112 (15.66 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high

    4.04 USD

  • Today low

    3.95 USD

  • 52 week high

    4.04 USD

  • 52 week low

    1.67 USD

  • YTD Change

    + 30.44 %

Quick links


Latest news about Banco Santander S.A. – ADR

Below you can find the most recent news posts about Banco Santander S.A. – ADR, primarily from US and UK based news sources.

Embrace Home Loans Hires Stephen Adamo as President of National Retail Production

Monday, 10 May 2021, 15:00:00
MIDDLETOWN, R.I. , May 10, 2021 /PRNewswire/ — Embrace Home Loans , a top-ranked national mortgage lender, announced that Stephen Adamo has joined the company as president, national retail production. He will be responsible for significantly increasing the company's retail sales force and expanding its retail footprint. Embrace originated a company record $6.4 billion in mortgage loans in 2020, a 70% increase from 2019. The company plans to double its retail production in 2021 and increase business in its consumer-direct and financial institutions group divisions, with a focus on purchase loans. Prior to joining Embrace, Adamo served as executive vice president, head of U.S. mortgage banking, home equity, consumer manufacturing and credit underwriting at Santander Bank, NA. In … Full story available on
— Benzinga

Covid furlough payment to help staff lost me mortgage

Monday, 10 May 2021, 08:00:41
Santander says it will not lend to the self-employed if they received government help in the past three months Coronavirus – latest updates See all our coronavirus coverage I desperately need some help after Santander declined our remortgage application. I have never earned more than I do now and business is booming. But our application has been refused because the company I part-own received two months’ furlough payments for an employee who had to reduce her hours because she could not get childcare. Our case is slightly complicated in that I both part-own and am employed by the seven-person firm, so Santander wanted to see my business details as well as my personal income. Our application was refused because the company had had government help. Continue reading…
— The Guardian

Sanofi's valuations attractive: Should you invest?

Monday, 3 May 2021, 03:00:00
Chronic therapeutic treatments contribute around 63% of Sanofi India’s domestic sales and the same is now under several restrictions due to the Covid-19 related disturbances. The company’s growth opportunities should improve once the situation stabilises and patients start coming back to the hospitals for treatment of other diseases. Despite short-term challenges, Sanofi continues to do well and was able to beat the street expectations with its results for the first quarter of 2021. While its q-o-q revenue remained stable, its y-o-y revenue declined by 8%. However, this decline was due to the divestment of its Ankleshwar plant and discontinuation of a few products to Zentiva. Its adjusted revenue growth is placed at 9% y-o-y. Its qo-q gross margin which declined mostly because of the increased contribution from low margin imports was offset by operational cost savings. Its q-o-q ebitda and net profit grew by 13% and 19% respectively. 82342643 !function(){“use strict”;window.addEventListener(“message”,(function(a){if(void 0![“datawrapper-height”])for(var e in[“datawrapper-height”]){var t=document.getElementById(“datawrapper-chart-“+e)||document.querySelector(“iframe[src*='”+e+”‘]”);t&&([“datawrapper-height”][e]+”px”)}}))}(); Despite being a mid-cap pharma company, analysts continue to impose their faith in Sanofi India due to its long term growth outlook.
— Economic Times India

Lloyds and Starling lead Q4 2020 UK account switches while taking opposite paths

Friday, 30 April 2021, 15:59:03
Summary List Placement Lloyds and Starling placed first and second, respectively, in receiving UK current account switchers during Q4 2020 by taking markedly different approaches with incentives, per AltFi. The data comes from the Current Account Switch Service (CASS), a free service that makes it easier to switch current accounts—which are similar to checking accounts in the US—and business accounts. CASS figures indicate that there were 704,560 account switches in the UK throughout 2020—a drop of approximately 300,000 from more than 1 million in 2019, likely caused by the coronavirus pandemic. However, Q4's performance indicates that account switching is bouncing back, closing with a crisis-era high of nearly 190,000. Lloyds Bank and Starling Bank both achieved success despite following different strategies for incentives: Lloyds was the Q4 leader, bringing in 29,556 net new accounts. Its success may have been driven by the £100 ($128.24) cash incentive for new customers that it unveiled last September.
— Business Insider

Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran

Wednesday, 28 April 2021, 19:27:23
Sanofi SA (NASDAQ: SNY ) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its delayed COVID-19 vaccine efforts. Earnings: Overall sales increased by 2.4%, attributed mainly to Dupixent’s success, with vaccines also contributing with a 5.3% rise in sales to €915 million. The Regeneron Pharmaceuticals Inc (NASDAQ: REGN )-partnered drug pulled in more than €1 billion worldwide for a year-over-year increase of 45.6% at the common exchange rate. Dupixent also scored a spot on China’s coveted National Reimbursement Drug List in March, marking the official launch of Dupixent in one of the world’s largest markets. Two of Sanofi’s … Full story available on
— Benzinga

Trading broker recommendation

We recommend that you check out as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: offer a large number of stocks for trading. Register an account today and check if they have SAN available or trade one of the many other CFD stocks they have.
Risk warning: 71.2% of retail investor accounts lose money when trading CFDs with Capital.